This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Regeneron Pharmaceuticals, Inc.. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Paola Mina-Osorio: Innovator in Dermatological Treatments
Introduction
Paola Mina-Osorio is a prominent inventor based in Guttenberg, NJ (US). She has made significant contributions to the field of dermatology, particularly in the treatment of atopic dermatitis. Her innovative approach has garnered attention in the medical community.
Latest Patents
Mina-Osorio holds a patent for "Methods for treating atopic dermatitis by administering an IL-4R antagonist antibody." This patent outlines methods for treating moderate-to-severe or severe atopic dermatitis in pediatric subjects. The methods involve administering one or more doses of an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or an antigen-binding fragment thereof. This groundbreaking work has the potential to improve the quality of life for many children suffering from this condition.
Career Highlights
Paola Mina-Osorio is currently associated with Regeneron Pharmaceuticals, Inc., where she continues to advance her research and development efforts. Her work at Regeneron has positioned her as a key player in the pharmaceutical industry, particularly in the area of immunology and dermatological treatments.
Collaborations
Mina-Osorio collaborates with esteemed colleagues such as Ashish Bansal and Neil John Graham. These partnerships enhance her research capabilities and contribute to the innovative solutions being developed at Regeneron.
Conclusion
Paola Mina-Osorio is a trailblazer in the field of dermatology, with her patent for treating atopic dermatitis showcasing her commitment to improving patient outcomes. Her work at Regeneron Pharmaceuticals, along with her collaborations, highlights her significant impact on medical research and innovation.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
